Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural killer cell direct cytotoxicity refers to the process by which NK cells identify and eliminate abnormal cells, such as virally infected or malignant cells. This is primarily achieved by the release of cytotoxic granules (containing perforin and granzymes) at the immunological synapse formed with the target cell, or by engagement of death receptors on target cells via molecules like Fas ligand and TRAIL. NK cell cytotoxicity is regulated by a balance of inhibitory and activating receptors, as well as by the availability of activating ligands on target cells. Dysregulation (either loss or excessive activity) of this function is implicated in diseases such as cancer, viral infections, and immunodeficiencies.
Perforin/granzyme-mediated cytotoxicity; Death receptor-mediated cytotoxicity (FasL, TRAIL); Antibody-dependent cell-mediated cytotoxicity (via CD16/FcγRIII)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer cell direct cytotoxicity.